MaxCyte, Inc. (NASDAQ: MXCT) is a Healthcare company (Biotechnology) with a market capitalization of $121M. The Maz Rating grades it against the other companies in its sector.
MaxCyte, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $1.17, MaxCyte, Inc. trades at 3.5x sales and 0.8x book value. Over the last twelve months it generated about $34M of revenue and a net loss of $27M. It runs a gross margin of 78.0%, an operating margin of -87.7% and a net margin of -81.4%. It shows return on equity of -17.2%, return on invested capital of -17.9% and a free cash flow yield of -17.8%. On the balance sheet: a debt-to-equity ratio of 0.11 and a current ratio of 7.83. Over the past 52 weeks the share price ranged from $0.64 to $1.81, with a beta of 1.48.
MaxCyte, Inc. does not currently pay a dividend.
6 Wall Street analyst ratings cover the stock: 4 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, MaxCyte, Inc. (MXCT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 98.8% / 30% · Interest income / Revenue 12.6% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 75.4% / 33% · Receivables / Mkt Cap (36m) 8.97% / 49% · Interest income / Revenue 12.6% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 75.4% / 33.33% · Receivables / Mkt Cap (24m) 8.97% / 33.33% · Interest income / Revenue 12.6% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 2.48% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 42.5% / 33.33% · Receivables / Avg Assets (4Q) 3.10% / 33.33% · Interest income / Revenue 12.6% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 55.5% / 33.33% · (Cash+Recv) / Total Assets 62.1% / 33.33% · Interest income / Revenue 12.6% / 5% | Fail |
No. As of September 2026, MaxCyte, Inc. (MXCT) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. MaxCyte, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 12.6% of each dividend: MaxCyte, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.